Personalized immunotherapy to fight HIV/AIDS

August 18, 2008

For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the McGill University Health Centre (MUHC), in collaboration with Dr. Rafick Sékaly from the Université de Montréal, have overcome this difficulty by designing a personalized immunotherapy for HIV-infected patients. The team's findings were presented on August 5 at the XVII International AIDS Conference in Mexico City.

"Our approach is unique in the world: no one else has yet developed customized immunotherapy using the virus from individual patients," said Dr. Routy. "This experimental technique remains long and costly for the moment, but we're hoping it will hold the promise of a completely innovative and widely available treatment in the future."

This immunotherapy is based on the properties of dendritic cells, whose role is to present specific proteins from infectious organisms at their surface, thereby alerting the rest of the immune system. In collaboration with Argos Therapeutics, the researchers designed a study in which the dendritic cells of nine study patients were multiplied in vitro and then treated with the RNA (ribonucleic acid) from the virus that had infected each patient. A virus sample was taken before the administration of any antiretroviral treatment.

The surfaces of these manipulated dendritic cells present an increased number of HIV proteins, which allows them to stimulate the cytotoxic response of a certain type of immune cell called CD8+ lymphocytes. After receiving multiple subcutaneous injections of these dendritic cells, eight of the nine patients involved experienced a significant increase in CD8+ lymphocyte activity.

"At this stage, we have shown that the technique doesn't cause side effects or an undesirable auto-immune response," said Dr. Routy. "Health Canada has approved a multicentre clinical trial across the country that will let us further assess the technique's effectiveness at controlling HIV reproduction. We're hoping that the FDA in the United States will also give us the go-ahead soon so that our pharmaceutical partner, Argos Therapeutics, can begin testing in the United States."

While more research needs to be done, this new target may lead to an innovative therapeutic approach to fight the AIDS pandemic.

McGill University Health Centre

Immunotherapy: Activation, Suppression and Treatments (Immunology and Immune System Dosorders)
by Blake C. Facinelli (Editor)

Immunotherapy is a medical term defined as 'treatment of disease by inducing, enhancing, or suppressing an immune response'. Immunotherapies are designed to elicit or amplify an immune response and are classified as activation immunotherapies. Immunotherapies designed to reduce, suppress or more appropriately direct an existing immune response, as in cases of autoimmunity or allergy, are classified as suppression immunotherapies. This book presents topical data on immunotherapies including: antifungal immunotherapy; active and specific immunotherapeutical strategies for the prevention and treatment of cancer; allergen immunotherapy; dendritic cell/tumour fusion cell vaccine in cancer therapy; CRLA-4 inhibition in malignant melanoma; and, others.

Allergen Immunotherapy, An Issue of Immunology and Allergy Clinics, 1e (The Clinics: Internal Medicine)
by Linda Cox MD (Author)

One hundred years have elapsed since specific allergen immunotherapy (SIT) was first employed and found to be effective in the treatment of allergic respiratory diseases. This cutting-edge issue of Immunology and Allergy Clinics offers a comprehensive review of this disease modifying treatment, exploring its history, status, and potential future. Topics covered include the mechanisms of subcutaneous allergen immunotherapy; the mechanisms of sublingual immunotherapy; optimizing efficacy of subcutaneous immunotherapy; preparation of allergen immunotherapy extraxcts; risk factors and subcutaneous immunotherapy safety; accelerated schedules and reducing risk with premedication (antihistamines, omalizumab, leucotriene antagonist); safety and efficacy of sublingual immunotherapy for allergic...

Cancer Immunology and Immunotherapy (Current Topics in Microbiology and Immunology)
by Glenn Dranoff (Editor)

The interplay between tumors and their immunologic microenvironment is complex, difficult to decipher, but its understanding is of seminal importance for the development of novel prognostic markers and therapeutic strategies. The present review discusses tumor-immune interactions in several human cancers that illustrate various aspects of this complexity and proposes an integrated scheme of the impact of local immune reactions on clinical outcome. Current active immunotherapy trials have shown durable tumor regressions in a fraction of patients. However, clinical efficacy of current vaccines is limited, possibly because tumors skew the immune system by means of myeloid-derived suppressor cells, inflammatory type 2 T cells and regulatory T cells (Tregs), all of which prevent the generation...

Immunotherapy of Cancer (Cancer Drug Discovery and Development)
by Mary L. Disis (Editor)

Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully...

Cancer Immunotherapy: Immune Suppression and Tumor Growth
by George C. Prendergast (Editor), Elizabeth M. Jaffee (Editor)

There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait...

The Low Dose Immunotherapy Handbook: Recipes and Lifestlye Advice for Patients on LDA and EPD Treatment
by Nicolette M Dumke (Author)

The Low Dose Immunotherapy Handbook: Recipes and Lifestyle Tips for Patients on LDA and EPD Treatment gives 80 recipes for patients on low dose immunotherapy treatment for their food allergies. These recipes are for the basic shot time (EPD) diet and the very mixed diet, and include baked goods, main dishes, and side dishes as well as allowable snacks, desserts and treats that make these diets more livable. It also includes organizational information to help you get ready for your shots and sources of special foods and products that low dose immunotherapy patients need.

Safe Allergen Immunotherapy: The Correct Allergen, The Appropriate Patient, The Adequate Dose (Postgraduate Medicine)
by JTE Multimedia

When patients have multiple sensitivitiesor allergy symptoms that are severe, year-round, and not adequately controlled by conventional drugs, physicians may consider immunotherapy. A number of conditions can render a patient a poor candidate for this treatment. But with careful screening for risk factors and equally careful diagnosis, administration, and dosage adjustment, allergen injection therapy can safely provide significant, long-lasting relief.

Original Publication Date: August 1996

Tumor Immunology: Immunotherapy and Cancer Vaccines (Cancer: Clinical Science in Practice)
by A. G. Dalgleish (Editor), M. J. Browning (Editor), Karol Sikora (Editor)

This volume reviews advances in the field of human tumor immunology, particularly in relation to the potential for immune intervention in preventing or treating tumors. The editors and contributors, all leading workers in the field, survey advances in the understanding of the relationship between the cancer cell and the immune response. Chapters review in depth the function of immune surveillance and mechanisms of tumor immunity, the role of T lymphocytes and oncogenes in the immune response to cancer, and the potential for immunotherapy of cancer. New areas of tumor immunology are presented, including recent progress in the development of tumor vaccines with particular reference to melanoma.

Cancer Immunotherapy, Volume 90 (Advances in Immunology)
by James Allison (Author), Glen Dranoff (Author)

For some time immunotherapy has been heralded as a breakthrough approach for cancer treatment. Although the potential of this strategy remains solid, the approach needs considerable refinement. Whilst some programmes are looking to increase the understanding of molecular and cellular mechanisms underlying the stimulation of antitumor immunity, others are trying to find the most appropriate clinical setting that will reveal the role of the immune system in combating cancer. Among the most important discoveries have been tumor-specific antigens.

This thematic volume highlights some key issues and discusses where they may move forward. It has been put together by two leading cancer immunotherapists from two eminent institutions that focus on cancer research.

MANAGING INSECT STING ALLERGY: The ins and outs of venom immunotherapy (Postgraduate Medicine)
by JTE Multimedia

Insect sting allergy can lead to severe, even fatal, reactions in susceptible persons. Although self-injection epinephrine often terminates the reaction, it is not always effective. In this article, Dr Graft explores the use of venom immunotherapy (VIT) in selected patients in whom successful treatment can produce psychosocial as well as physiologic benefits.

Original Publication Date: July 2005